• 94% of participants maintained seroresponse five years after a single vaccination
• Comparable antibody persistence observed in older (65+) and younger adults
• Data further reinforce IXCHIQ®'s differentiated profile with durable antibody persistence against an unpredictable outbreak disease

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.